A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?

Author： Kontoghiorghes George J  

Publisher： Informa Healthcare

ISSN： 1474-0338

Source： Expert Opinion on Drug Safety, Vol.12, Iss.5, 2013-09, pp. : 605-609

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Comment on: A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?

By Riva Alessandro  

Expert Opinion on Drug Safety, Vol. 12, Iss. 5, 2013-09 ,pp. : 793-795

Informa Healthcare

Access to resources Recommend Favorite

Finland's regulatory agency receives record number of ADR reports

By  

Inpharma, Vol. 1, Iss. 1487, 2005-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

Deferasirox: Liver injury in a patient with haemochromatosis: case report

By  

Reactions Weekly, Vol. 1, Iss. 1329, 2010-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

Post Marketing Surveillance on Safety and Efficacy of IMOD in Iranian Patients with HIV/AIDS

By  

Infectious Disorders - Drug Targets (Formerly Current Drug Targets - Infectious Disorders), Vol. 13, Iss. 1, 2013-02 ,pp. : 71-74

Bentham Science Publishers

Access to resources Recommend Favorite

Safety Profile of Meropenem: An Updated Review of Over 6000 Patients Treated with Meropenem

By Linden Peter  

Drug Safety, Vol. 30, Iss. 8, 2007-01 ,pp. : 657-668

Adis International

Access to resources Recommend Favorite